Advanced

Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma.

Jiang, Jingting; Wu, Changping; Shen, Yueping; Xu, Bin; Zheng, Xiao; Li, Xiaodong and Xu, Ning LU (2011) In Anticancer Research 31(2). p.687-691
Abstract
Diagnosis of primary hepatocellular carcinoma (HCC) at early stages has obviously been improved since determination of serum levels of free alpha-fetoprotein (AFP) was implemented. AFP has been considered as the standard tumor marker of primary HCC, although certain patients have very low serum free AFP levels. In the present study, clinical application of measuring serum AFP-IgM immune complexes compared to the serum free AFP was evaluated for diagnosis of small HCC. One hundred and three healthy controls, 74 patients with primary HCC, 27 patients with liver cirrhosis and 63 patients with chronic hepatitis were included in the present study. Serum levels of AFP-IgM immune complexes and free AFP were determined by ELISA and... (More)
Diagnosis of primary hepatocellular carcinoma (HCC) at early stages has obviously been improved since determination of serum levels of free alpha-fetoprotein (AFP) was implemented. AFP has been considered as the standard tumor marker of primary HCC, although certain patients have very low serum free AFP levels. In the present study, clinical application of measuring serum AFP-IgM immune complexes compared to the serum free AFP was evaluated for diagnosis of small HCC. One hundred and three healthy controls, 74 patients with primary HCC, 27 patients with liver cirrhosis and 63 patients with chronic hepatitis were included in the present study. Serum levels of AFP-IgM immune complexes and free AFP were determined by ELISA and electrochemiluminescence, respectively. The best cut-off values of AFP-IgM immune complexes and free AFP for the diagnosis of primary HCC were 300 AU/ml and 10 μg/l, respectively, according to the area under the curve (AUC). At these cut-off values, the sensitivities of AFP-IgM and AFP for HCC were 64.9% and 79.7%, respectively, with specificities of 75.6% and 80.3%, respectively. Combining positivity for both tumor markers, the specificity and accuracy of diagnosis of HCC were 89.1% and 79.0%, respectively. Moreover, when the diameter of the tumor was ≤3 cm (being considered as small HCC), the sensitivity and specificity were 100.0% and 75.3%, respectively. There was no significant correlation between AFP-IgM level, patient sex or age (p>0.05). The ROC area was significantly different between AFP-IgM and AFP (Z=2.19, p=0.0286). In addition, the serum AFP-IgM levels were significantly higher in the patients with tumor diameter ≤3 cm (1090.4±571.8 AU/ml) than in the patients with tumor diameter >3 cm (604.9±749.9 AU/ml). It is concluded that determining serum levels of both AFP-IgM immune complex and AFP may have potential benefit for the diagnosis of small HCC. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Anticancer Research
volume
31
issue
2
pages
687 - 691
publisher
International Institute of Cancer Research
external identifiers
  • pmid:21378357
  • wos:000288684800043
  • scopus:79953237655
ISSN
1791-7530
language
English
LU publication?
yes
id
3c8dc05c-8c57-4e3e-a438-664ab50dd7c0 (old id 1884327)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21378357?dopt=Abstract
date added to LUP
2011-04-01 13:38:20
date last changed
2017-11-05 04:41:16
@article{3c8dc05c-8c57-4e3e-a438-664ab50dd7c0,
  abstract     = {Diagnosis of primary hepatocellular carcinoma (HCC) at early stages has obviously been improved since determination of serum levels of free alpha-fetoprotein (AFP) was implemented. AFP has been considered as the standard tumor marker of primary HCC, although certain patients have very low serum free AFP levels. In the present study, clinical application of measuring serum AFP-IgM immune complexes compared to the serum free AFP was evaluated for diagnosis of small HCC. One hundred and three healthy controls, 74 patients with primary HCC, 27 patients with liver cirrhosis and 63 patients with chronic hepatitis were included in the present study. Serum levels of AFP-IgM immune complexes and free AFP were determined by ELISA and electrochemiluminescence, respectively. The best cut-off values of AFP-IgM immune complexes and free AFP for the diagnosis of primary HCC were 300 AU/ml and 10 μg/l, respectively, according to the area under the curve (AUC). At these cut-off values, the sensitivities of AFP-IgM and AFP for HCC were 64.9% and 79.7%, respectively, with specificities of 75.6% and 80.3%, respectively. Combining positivity for both tumor markers, the specificity and accuracy of diagnosis of HCC were 89.1% and 79.0%, respectively. Moreover, when the diameter of the tumor was ≤3 cm (being considered as small HCC), the sensitivity and specificity were 100.0% and 75.3%, respectively. There was no significant correlation between AFP-IgM level, patient sex or age (p>0.05). The ROC area was significantly different between AFP-IgM and AFP (Z=2.19, p=0.0286). In addition, the serum AFP-IgM levels were significantly higher in the patients with tumor diameter ≤3 cm (1090.4±571.8 AU/ml) than in the patients with tumor diameter >3 cm (604.9±749.9 AU/ml). It is concluded that determining serum levels of both AFP-IgM immune complex and AFP may have potential benefit for the diagnosis of small HCC.},
  author       = {Jiang, Jingting and Wu, Changping and Shen, Yueping and Xu, Bin and Zheng, Xiao and Li, Xiaodong and Xu, Ning},
  issn         = {1791-7530},
  language     = {eng},
  number       = {2},
  pages        = {687--691},
  publisher    = {International Institute of Cancer Research},
  series       = {Anticancer Research},
  title        = {Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma.},
  volume       = {31},
  year         = {2011},
}